AngioSoma Inc
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, engages in the provision of patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases in the United States. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is base… Read more
AngioSoma Inc (GSTC) - Total Assets
Latest total assets as of September 2024: $83.87K USD
Based on the latest financial reports, AngioSoma Inc (GSTC) holds total assets worth $83.87K USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
AngioSoma Inc - Total Assets Trend (2010–2023)
This chart illustrates how AngioSoma Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
AngioSoma Inc - Asset Composition Analysis
Current Asset Composition (September 2023)
AngioSoma Inc's total assets of $83.87K consist of 0.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2023)
This chart illustrates how AngioSoma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AngioSoma Inc's current assets represent 0.0% of total assets in 2023, a decrease from 100.0% in 2010.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2023, down from 100.0% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2010.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
AngioSoma Inc Competitors by Total Assets
Key competitors of AngioSoma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
AngioSoma Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - AngioSoma Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - AngioSoma Inc is currently not profitable relative to its asset base.
AngioSoma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.05 | 0.00 | 0.13 |
| Quick Ratio | 0.05 | 0.00 | 0.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.62 Million | $ -1.43 Million | $ -618.30K |
AngioSoma Inc - Advanced Valuation Insights
This section examines the relationship between AngioSoma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -100.0% |
| Total Assets | $0.00 |
| Market Capitalization | $124.11K USD |
Valuation Analysis
Below Book Valuation: The market values AngioSoma Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: AngioSoma Inc's assets decreased by 100.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for AngioSoma Inc (2010–2023)
The table below shows the annual total assets of AngioSoma Inc from 2010 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-09-30 | $0.00 | -- |
| 2022-12-31 | $9.91K | 0.00% |
| 2022-09-30 | $9.91K | +66.36% |
| 2021-12-31 | $5.96K | 0.00% |
| 2021-09-30 | $5.96K | -93.37% |
| 2020-12-31 | $89.91K | 0.00% |
| 2020-09-30 | $89.91K | -36.76% |
| 2019-09-30 | $142.18K | +13.98% |
| 2018-09-30 | $124.75K | +408.06% |
| 2017-09-30 | $24.55K | +42.18% |
| 2016-09-30 | $17.27K | -94.64% |
| 2015-09-30 | $322.31K | -32.51% |
| 2014-09-30 | $477.60K | +3.25% |
| 2013-09-30 | $462.56K | +63.96% |
| 2012-09-30 | $282.12K | +1185.77% |
| 2011-09-30 | $21.94K | +145.93% |
| 2010-09-30 | $8.92K | -- |